PBA
BBOT

Paradigm Biocapital Advisors’s BridgeBio Oncology BBOT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-868,213
Closed -$7.77M – 39
2026
Q1 		$7.77M Sell
868,213
-1,393,536
-62% -$15M 0.16% 34
2025
Q4 		$28.3M Buy
2,261,749
+395,608
+21% +$4.79M 0.72% 25
2025
Q3 		$21.6M Buy
+1,866,141
New +$19.4M 0.61% 33

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paradigm Biocapital Advisors's BBOT Position: Q2 2026 in Review

Paradigm Biocapital Advisors sold out of BridgeBio Oncology (BBOT) in Q2 2026, closing a stake of 868,213 shares — an estimated $7.77M sold.

Paradigm Biocapital Advisors first reported a position in BBOT in Q3 2025 and held it in 3 quarters. The position peaked at $28.3M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Paradigm Biocapital Advisors reported no remaining BridgeBio Oncology position as of Q2 2026 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 868,213 BridgeBio Oncology shares in Q2 2026, an estimated $7.77M.
  • Paradigm Biocapital Advisors first reported a position in BridgeBio Oncology in Q3 2025 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's BridgeBio Oncology position peaked at $28.3M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.